Tim McCaffery Appointed as Advisory Board Member at Lysando

Triesenberg, Liechtenstein, July 17, 2024 – Lysando AG, a leading innovator in antimicrobial solutions, is pleased to announce the appointment of Tim McCaffery to its Advisory Board. McCaffery, a seasoned expert in deep technology and life sciences investments, brings a wealth of experience and strategic insight to the Lysando team.

Tim McCaffery currently manages SCG's Deep Technology and Life Sciences Corporate Venture Capital (CVC) funds, which encompass over seven Limited Partner (LP) relationships with venture capital firms and more than fifteen portfolio companies. SCG's Deep Technology CVC dedicated to investing in breakthrough decarbonization technologies, including clean energy generation, storage, carbon capture, utilization and storage batteries, circular industrial (CCUS), economy, and biotechnology.

Prior to his current role, McCaffery led SCG Chemicals Deep Technology Investing and SCG Chemicals Functional Materials and Battery Materials businesses. McCaffery's extensive career also includes his tenure at Cabot Corporation, a U.S.-based materials company. His diverse experience spans roles as a startup founder, positions in large corporations both in the U.S. and internationally, and service in the U.S. Army.

Academically, Tim McCaffery holds an MBA from MIT's Sloan School of Management, an MS in Materials Science from the University of New Hampshire, and a BS in Chemical Engineering from the University of New Hampshire.

"I am pleased to join the Advisory Board of Lysando. The company has impressive technology for the control of bacteria which has many applications in skincare, wound care and can improve many lives around the world," said Tim McCaffery.

McCaffery's appointment comes at a pivotal time for Lysando as the company accelerates its efforts to combat antimicrobial resistance with its Artilysin® technology, offering effective and sustainable solutions for healthcare, agriculture, and industrial applications.

About Lysando AG

Lysando AG is market leader for antimicrobial proteins, Artilysin® molecules, which can effectively manage problem-causing bacteria without associated risk of resistance formation and microbial disbalances. Artilysin® constitutes an innovative, proprietary, and environmentally friendly technology with a wide range of applications.